Standout Papers

Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease 2001 2026 2009 2017 1.4k
  1. Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease (2001)
    Ramachandran S. Vasan, Martin G. Larson et al. New England Journal of Medicine
  2. Lifetime Risk for Development of Atrial Fibrillation (2004)
    Donald M. Lloyd‐Jones, Thomas J. Wang et al. Circulation
  3. Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality (2003)
    Thomas J. Wang, Martin G. Larson et al. Circulation
  4. Plasma Natriuretic Peptide Levels and the Risk of Cardiovascular Events and Death (2004)
    Thomas J. Wang, Martin G. Larson et al. New England Journal of Medicine
  5. Lifetime Risk for Developing Congestive Heart Failure (2002)
    Donald M. Lloyd‐Jones, Martin G. Larson et al. Circulation
  6. Does the Relation of Blood Pressure to Coronary Heart Disease Risk Change With Aging? (2001)
    Stanley S. Franklin, Martin G. Larson et al. Circulation
  7. Prediction of Lifetime Risk for Cardiovascular Disease by Risk Factor Burden at 50 Years of Age (2006)
    Donald M. Lloyd‐Jones, Eric Leip et al. Circulation
  8. Impact of Obesity on Plasma Natriuretic Peptide Levels (2004)
    Thomas J. Wang, Martin G. Larson et al. Circulation
  9. Assessment of frequency of progression to hypertension in non-hypertensive participants in the Framingham Heart Study: a cohort study (2001)
    Ramachandran S. Vasan, Martin G. Larson et al. The Lancet
  10. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial (2017)
    Jörge E. Cortes, Carlo Gambacorti‐Passerini et al. Journal of Clinical Oncology

Immediate Impact

130 standout
Sub-graph 1 of 11

Citing Papers

Global Effect of Cardiovascular Risk Factors on Lifetime Estimates
2025 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout
8 intermediate papers

Works of Eric Leip being referenced

Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM).
2022
Lifetime Risk for Developing Congestive Heart Failure
2002 Standout
and 4 more

Author Peers

Author Last Decade Papers Cites
Eric Leip 1614 1228 882 9604 1429 114 14.1k
Hocine Tighiouart 998 357 417 3512 1469 176 14.2k
Eldrin F. Lewis 1712 670 199 7163 3182 216 16.1k
Sunil Bhandari 1636 1076 276 4300 1660 201 11.1k
Dominique Arveiler 1293 361 495 5897 4357 247 15.3k
Kenneth Dickstein 1644 703 253 8418 1075 161 11.5k
Lawrence G. Hunsicker 593 466 798 7439 5286 132 18.6k
Bruce F. Culleton 763 309 588 3349 1048 92 11.5k
Geoffrey H. Tofler 892 141 316 6706 1611 197 13.2k
Alun Evans 899 226 768 3119 2118 107 9.2k
Kunitoshi Iseki 923 317 550 2795 1755 319 12.8k

All Works

Loading papers...

Rankless by CCL
2026